Goldstein Advisors LLC Decreases Stock Position in Natera, Inc. (NASDAQ:NTRA)

Goldstein Advisors LLC reduced its position in Natera, Inc. (NASDAQ:NTRA) by 9.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,974 shares of the medical research company’s stock after selling 213 shares during the period. Goldstein Advisors LLC’s holdings in Natera were worth $312,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Quarry LP raised its stake in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after buying an additional 190 shares during the last quarter. Versant Capital Management Inc raised its stake in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after buying an additional 166 shares during the last quarter. Covestor Ltd raised its stake in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the last quarter. GAMMA Investing LLC raised its stake in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares during the last quarter. Finally, True Wealth Design LLC purchased a new stake in Natera during the 3rd quarter valued at $57,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Trading Up 2.7 %

Shares of Natera stock opened at $171.93 on Thursday. The company has a market capitalization of $22.70 billion, a P/E ratio of -97.69 and a beta of 1.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a fifty day moving average of $165.35 and a 200 day moving average of $135.41. Natera, Inc. has a fifty-two week low of $62.96 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.95) EPS. On average, sell-side analysts anticipate that Natera, Inc. will post -1.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on NTRA shares. Leerink Partners boosted their target price on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Barclays assumed coverage on shares of Natera in a research note on Thursday. They set an “overweight” rating and a $200.00 target price for the company. Canaccord Genuity Group boosted their price objective on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Finally, Sanford C. Bernstein boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, January 10th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $162.94.

Insiders Place Their Bets

In other Natera news, insider Solomon Moshkevich sold 1,196 shares of the business’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $141,379.16. Following the sale, the insider now owns 110,695 shares in the company, valued at $13,085,255.95. The trade was a 1.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gail Boxer Marcus sold 2,212 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now owns 19,386 shares in the company, valued at approximately $3,073,262.58. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 224,824 shares of company stock worth $36,912,749 in the last 90 days. 7.60% of the stock is currently owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.